Clinical Trials
14 trialsNCT03370406 2026-06-01
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
University of Pittsburgh
Phase 1 Recruiting
NCT05977998 2026-05-22
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06959706 2026-04-16
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT07400263 2026-03-30
Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors
Peking University People's Hospital
Phase NA Recruiting
NCT05065736 2026-03-19
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06128343 2026-03-19
BACAP-2
University Hospital, Toulouse
Recruiting
NCT00349830 2026-02-10
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford University
Recruiting
NCT05283226 2026-01-23
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Phase 2 Recruiting
NCT06612827 2025-12-24
OCAPI
Centre Francois Baclesse
Recruiting
NCT06969534 2025-05-15
Safety and Efficacy of Pucotenlimab in pLECC
Sun Yat-sen University
Phase 2 Recruiting
NCT05917158 2025-01-22
1
Jinling Hospital, China
Phase 2 Recruiting
NCT05141474 2024-11-07
NEXTGENTIL-ACT
Vall d'Hebron Institute of Oncology
Phase EARLY_PHASE1 Recruiting
NCT02292641 2024-10-17
Beyond TME Origins
Imperial College London
Phase NA Recruiting
NCT06013111 2024-02-21
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
China Medical University, China
Phase 1 Recruiting